how many people are on glp 1 take drugs GLP-1 Drugs Market Size to Hit USD 132.79 Poll: 1 in 8 Adults

She switched to the Wegovy pill because her health insurance changed, meaning that she would go from paying $25 a month to $449 a month for Zepbound

Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch

Those who have kidney disease

Long-term safety data remain limited

Some of those side effects include ileus and gastroparesis, which can require hospitalization or surgery to treat

And now Foundayo seems like it may have similar safety data - we have topline results from ACHIEVE-4 showing Foundayo seems to have a beneficial impact on cardiovascular disease, at least compared to insulin treatment.1 And ACHIEVE-4 showed a 57% reduction in all cause death